ChinaBio Today -- Asymchem Laboratories Inc., a privately held CMO/CRO headquartered in North Carolina but with its operations centered in China, has begun construction of a new $34.6 million API manufacturing facility in Jilin province, the company’s seventh facility in China. Meanwhile, the recent heparin scandal is having an effect on the API business in China. More details...
